Literature DB >> 25883801

Chemokine levels and parasite- and allergen-specific antibody responses in children and adults with severe or uncomplicated Plasmodium falciparum malaria.

B Wangala, A Vovor, R G Gantin, Y F Agbeko, C J Lechner, X Huang, P T Soboslay, C Köhler.   

Abstract

Chemokine and antibody response profiles were investigated in children and adults with severe or uncomplicated Plasmodium falciparum malaria; the aim was to reveal which profiles are associated with severe disease, as often seen in nonimmune children, or with mild and uncomplicated disease, as seen in semi-immune adults. Blood samples were obtained from children under 5 years of age as well as adults with falciparum malaria. Classification of malaria was performed according to parasite densities and hemoglobin concentrations. Plasma levels of chemokines (IL-8, IP-10, MCP-4, TARC, PARC, MIP-1δ, eotaxins) were quantified, and antibody responses (IgE, IgG1, and IgG4) to P. falciparum, Entamoeba histolytica-specific antigen, and mite allergen extracts were determined. In children with severe malaria proinflammatory, IL-8, IP10, MIP-1δ, and LARC were at highly elevated levels, suggesting an association with severe disease. In contrast, the Th2-type chemokines TARC, PARC, and eotaxin-2 attained in children the same levels as in adults suggesting the evolution of immune regulatory components. In children with severe malaria, an elevated IgG1 and IgE reactivity to mite allergens and intestinal protozoan parasites was observed. In conclusion, exacerbated proinflammatory chemokines together with IgE responses to mite allergens or E. histolytica-specific antigen extract were observed in children with severe falciparum malaria.

Entities:  

Keywords:  Plasmodium falciparum; antibody; chemokine; children; malaria

Year:  2015        PMID: 25883801      PMCID: PMC4397855          DOI: 10.1556/EUJMI-D-14-00041

Source DB:  PubMed          Journal:  Eur J Microbiol Immunol (Bp)        ISSN: 2062-509X


  53 in total

1.  Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria.

Authors:  Faith H A Osier; Gregory Fegan; Spencer D Polley; Linda Murungi; Federica Verra; Kevin K A Tetteh; Brett Lowe; Tabitha Mwangi; Peter C Bull; Alan W Thomas; David R Cavanagh; Jana S McBride; David E Lanar; Margaret J Mackinnon; David J Conway; Kevin Marsh
Journal:  Infect Immun       Date:  2008-03-03       Impact factor: 3.441

2.  Interleukin-8 and Plasmodium falciparum malaria in Thailand.

Authors:  J S Friedland; M Ho; D G Remick; D Bunnag; N J White; G E Griffin
Journal:  Trans R Soc Trop Med Hyg       Date:  1993 Jan-Feb       Impact factor: 2.184

Review 3.  Contribution of allergic inflammatory response to the pathogenesis of malaria disease.

Authors:  Salaheddine Mecheri
Journal:  Biochim Biophys Acta       Date:  2011-02-23

4.  Differential regulation of beta-chemokines in children with Plasmodium falciparum malaria.

Authors:  Daniel O Ochiel; Gordon A Awandare; Christopher C Keller; James B Hittner; Peter G Kremsner; J Brice Weinberg; Douglas J Perkins
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

5.  Hemozoin induces lung inflammation and correlates with malaria-associated acute respiratory distress syndrome.

Authors:  Katrien Deroost; Ariane Tyberghein; Natacha Lays; Sam Noppen; Evelin Schwarzer; Els Vanstreels; Mina Komuta; Mauro Prato; Jing-Wen Lin; Ana Pamplona; Chris J Janse; Paolo Arese; Tania Roskams; Dirk Daelemans; Ghislain Opdenakker; Philippe E Van den Steen
Journal:  Am J Respir Cell Mol Biol       Date:  2013-05       Impact factor: 6.914

6.  Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan.

Authors:  Nnaemeka C Iriemenam; Atif H Khirelsied; Amre Nasr; Gehad ElGhazali; Haider A Giha; Thoraya M Elhassan A-Elgadir; Ahmed A Agab-Aldour; Scott M Montgomery; Robin F Anders; Michael Theisen; Marita Troye-Blomberg; Mustafa I Elbashir; Klavs Berzins
Journal:  Vaccine       Date:  2008-10-31       Impact factor: 3.641

7.  Malaria modifies neonatal and early-life toll-like receptor cytokine responses.

Authors:  Komi Gbédandé; Stefania Varani; Samad Ibitokou; Parfait Houngbegnon; Sophie Borgella; Odilon Nouatin; Sem Ezinmegnon; Adicatou-Laï Adeothy; Gilles Cottrell; Achille Massougbodji; Kabirou Moutairou; Marita Troye-Blomberg; Philippe Deloron; Nadine Fievet; Adrian J F Luty
Journal:  Infect Immun       Date:  2013-05-20       Impact factor: 3.441

Review 8.  T cell-derived IL-10 and its impact on the regulation of host responses during malaria.

Authors:  Ana Paula Freitas do Rosario; Jean Langhorne
Journal:  Int J Parasitol       Date:  2012-04-24       Impact factor: 3.981

9.  Duality and complexity of allergic type inflammatory mechanisms in determining the outcome of malaria disease.

Authors:  Ulrich Blank; Salaheddine Mécheri
Journal:  Front Immunol       Date:  2011-12-23       Impact factor: 7.561

10.  Increase of malaria attacks among children presenting concomitant infection by Schistosoma mansoni in Senegal.

Authors:  Cheikh Sokhna; Jean-Yves Le Hesran; Pape A Mbaye; Jean Akiana; Pape Camara; Mamadou Diop; Abdoulaye Ly; Pierre Druilhe
Journal:  Malar J       Date:  2004-11-15       Impact factor: 2.979

View more
  2 in total

1.  Monocyte polarization in children with falciparum malaria: relationship to nitric oxide insufficiency and disease severity.

Authors:  J Brice Weinberg; Alicia D Volkheimer; Matthew P Rubach; Salvatore M Florence; Jackson P Mukemba; Ayam R Kalingonji; Charles Langelier; Youwei Chen; Margaret Bush; Tsin W Yeo; Donald L Granger; Nicholas M Anstey; Esther D Mwaikambo
Journal:  Sci Rep       Date:  2016-07-07       Impact factor: 4.379

2.  Early detection of neonatal group B streptococcus sepsis and the possible diagnostic utility of IL-6, IL-8, and CD11b in a human umbilical cord blood in vitro model.

Authors:  Britt Nakstad; Tonje Sonerud; Anne Lee Solevåg
Journal:  Infect Drug Resist       Date:  2016-07-08       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.